Hard to Treat Diseases, Inc.
(Public, PINK:HTDS)
With the upcoming flu season upon us (considered between October and May with the peak of the season falling between late December and March), StocksHaven Investments highlights one of the most undervalued pink sheet penny biomedical stocks available, which not only tackles influenza treatments, but also many other harmful and dangerous viruses and infections. Hard to Treat Diseases is unlike any other company we have profiled before — rather than concentrating and manufacturing its own drugs for research and development purposes, it focuses on being a parent company for two subsidiaries: Slavica Bio Chem Co. and China Mellow Hope Inc.
About
The company operates 2 medical subsidiaries in Serbia, Europe and Mainland ChinaHTDS is a parent co with operations in a East European medical company (Serbia) Slavica Bio Chem Co (formerly ReNuYu Biochmem PLC and ReNuYu Biochem Inc) see: (www.slavicabiochem.com) and in China Mellow Hope Inc. www.mellowhope.com In Serbia the company’s primary focus involves the enhancement and modification of existing approved drugs such as “Virazole” for the purpose of chemical repair of damage to the CNS (central nervous system), MS (Multiple Sclerosis), SARS, Hepatitis C and HIV. Other interests include an on line cosmetics company.Mellow Hope is China based and the biggest exporter of Biological Vaccines in China. It has a product line that encompasses vaccines for influenza, tetanus, diphtheria and other diseases; Blood based products including human rabies immunoglobulin; and active pharmaceutical ingredient (or APIs) for injection such as celestat in.
Slavica Bio Chem Co.
-
Currently are engaged in the research and development of the following applications: Primary focus is on the chemical repair of damage to the CNS (central nervous system), MS (Multiple Sclerosis) SARS, Hepatitis C, HIV through the enhancement of already approved drugs such as “Virazole”. Tiazofurin is in Phase II of clinical trials as a anticancer drug.
-
Secondary or “retail” product line is the development of a cosmeticeutical method enabling painless removal of pigmented moles from the face and body. Through the branch company in Spain (ReNuYu Espana Biochem SA) they plan to offer a “day clinic spa type” facility and service in Marbella Spain where clients can painlessly and with non surgical means remove birthmarks.
-
Slavica Biochem is involved aiding in the research and development of “Interferon Apha”. Simply put, Interferon alpha is purified polypeptide, which is prepared from leukocytes of a peripherial healthy human blood. Interferon is the first natural human body defense from foreign substances as microorganisms, tumors, and antigenes. Beside antiviral effects, interferon plays an important role in the battle against tumors and with others cytokines take part in various processes in a human body. This medicine is used in the forms of injections, cream and eye drops.
Shenzhen Mellow Hope Pharm Industrial Co., Ltd.
Shenzhen Mellow Hope Pharm Industrial Co., Ltd, specializing in Biological Vaccines, has established a global brand in the biological vaccine industry, and operates in vaccine-related R&D, purchasing, sales, product registration, clinical trials, brand promotions, and marketing. After nearly ten-year unremitting efforts, Mellow Hope has grown to be one of the biggest exporters of vaccines in China.
Vacines
Other Biological Products
To-be-launched Products
Latest News and Developments
SHENZHEN, China, July 15, 2009 /PRNewswire-FirstCall via COMTEX/ — Hard to Treat Diseases (HTDS.PK) www.htdsmedical.com announced today that the company is now preparing for the tender business of 250,000 doses of MEVAC-ACYW in Indonesia.The product specifications and details can be viewed by visiting this web page directly http://www.mellowhope.com/en/ProductView.asp?ID=51.This is the second completed batch exported to Indonesia this year by the company. The first batch was delivered to Indonesia in December 2008. At that time, the company successfully exported 70,000 doses of the product to Indonesia. Mr. Terry Yan CEO of HTDS said “The positive feedback of our product will help us to win the tender again this year. Our European division Slavica Bio Chem continues with its research and we are hopeful to release some further details of their work shortly.”
—-
July 13, 2009: Hard to Treat Diseases (HTDS.PK) www.htdsmedical.com – subsidiary, Mellow Hope signed an agreement with Yunnan Walvax Biotech Co., Ltd for the Haemophilus influenza type b conjugate vaccine. Yunnan Walvax Biotech Co. Ltd is the second biggest manufacturer of Haemophilus influenza type b conjugate vaccine in China. This agreement / arrangement now sets the stage for Mellow Hope to be fully authorized to conduct the international marketing of Haemophilus influenza type b conjugate vaccine in the global market. In other corporate news, the company plans on commencing the registration in Chile, Indonesia, Egypt, and Russia within this month with the brand name “MEVAC-Hib”.
Reasserting Multi Million Dollar IP Ownership Rights
Intellectual property (IP) are legal property rights over creations of the mind, both artistic and commercial, and the corresponding fields of law. Under intellectual property law, owners are granted certain exclusive rights to a variety of intangible assets, such as musical, literary, and artistic works; ideas, discoveries and inventions; and words, phrases, symbols, and designs. Common types of intellectual property include copyrights, trademarks, patents, industrial design rights and trade secrets.
The company announced that as previously released on June 24, 2009, it is in the process of reasserting its ownership rights to certain intellectual property, which was inappropriately converted by the previous management of HTDS. 100% of the ownership rights are expected to be assigned back to HTDS. The following SEC filing http://www.pinksheets.com/edgar/GetFilingHtml?FilingID=652915 dated June 2, 2000 together with the activities of certain X employees and the aforementioned technology is the scope of the IP ownership rights and benefits’.The IP rights are being utilized by a fully reporting OTCBB publicly traded company. As a result of HTDS IP rights, this company has raised over $14 million in equity financing, constructed an operating plant that generates revenue, is in the process of purchasing parcels of property in various States in order to construct additional plants and has had numerous industrial bonds approved for an average amount of $10 million each.
Once the rights have been reasserted by HTDS, various projections (based on confidential financial documents and projections of the OTCBB company) indicates gross revenue exceeding $250 million, gross profit exceeding $220 million and net income exceeding $40 million within two years.
Overall Sentiment
With the price rising nearly 100% during the past three months, Hard to Treat Diseases should see a decent run in price, continuing its strong trend. Investors need to maintain a keen eye on press releases from the company with regards to the ongoing efforts in partnerships, and cash infusions in order to maintain operations from both subsidiaries. Short-term outlook may seem troubling, but in the long-term this company has many escape routers for success thus ensuring a safe bet for steady gains.
—–
Disclosure: No Positions
—–
By reading StocksHaven Investments you agree to the disclaimer, and thereby will not hold Michael Vlaicu accountable for any transactions or decisions you make. It is up to you to do your own due diligence.
|
About Michael: A young and savvy, yet experienced and accomplished investments mogul since ‘01; Michael has amassed a fortune as a private self investor. Recently starting his own successful blog and turning it in to a corporation — MIV Investments Inc., a company offering advice to thousands of people worldwide and attracting contracts from various reputable sources. His articles and publications have been linked to Forbes, CNN Money, Reuters, Bloomberg, and many other top worldwide mainstream media sources. |
